Optimized Preload Leakage-Correction Methods to Improve the Diagnostic Accuracy of Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging in Posttreatment Gliomas

L.S. Hu, L.C. Baxter, D.S. Pinnaduwage, T.L. Paine, J.P. Karis, B.G. Feuerstein, K.M. Schmainda, A.C. Dueck, J. Debbins, K.A. Smith, P. Nakaji, J.M. Eschbacher, S.W. Coons and J.E. Heiserman

AJNR Am J Neuroradiol 2010, 31 (1) 40-48
doi: https://doi.org/10.3174/ajnr.A1787
http://www.ajnr.org/content/31/1/40
Optimized Preload Leakage-Correction Methods to Improve the Diagnostic Accuracy of Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging in Posttreatment Gliomas

BACKGROUND AND PURPOSE: Relative cerebral blood volume (rCBV) accuracy can vary substantially depending on the dynamic susceptibility-weighted contrast-enhanced (DSC) acquisition and postprocessing methods, due to blood-brain barrier disruption and resulting T1-weighted leakage and T2- and/or T2*-weighted imaging (T2/T2*WI) residual effects. We set out to determine optimal DSC conditions that address these errors and maximize rCBV accuracy in differentiating posttreatment radiation effect (PTRE) and tumor.

MATERIALS AND METHODS: We recruited patients with previously treated high-grade gliomas undergoing image-guided re-resection of recurrent contrast-enhancing MR imaging lesions. Thirty-six surgical tissue samples were collected from 11 subjects. Preoperative 3T DSC used 6 sequential evenly timed acquisitions, each by using a 0.05-mmol/kg gadodiamide bolus. Preload dosing (PLD) and baseline subtraction (BLS) techniques corrected T1-weighted leakage and T2/T2*WI residual effects, respectively. PLD amount and incubation times increased with each sequential acquisition. Corresponding tissue specimen stereotactic locations were coregistered to DSC to measure localized rCBV under varying PLD amounts, incubation times, and the presence of BLS. rCBV thresholds were determined to maximize test accuracy (average of sensitivity and specificity) in distinguishing tumor (n = 21) and PTRE (n = 15) samples under the varying conditions. Receiver operator characteristic (ROC) areas under the curve (AUCs) were statistically compared.

RESULTS: The protocol that combined PLD (0.1-mmol/kg amount, 6-minute incubation time) and BLS correction methods maximized test AUC (0.99) and accuracy (95.2%) compared with uncorrected rCBV AUC (0.88) and accuracy (81.0%) measured without PLD and BLS (P = .01).

CONCLUSIONS: Combining PLD and BLS correction methods for T1-weighted and T2/T2*WI errors, respectively, enables highly accurate differentiation of PTRE and tumor growth.

Dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging (DSC) offers important imaging biomarkers to evaluate high-grade gliomas in the posttreatment setting. Tumor recurrence and posttreatment radiation effect (PTRE) both demonstrate contrast-enhancing MR imaging lesions, which are often indistinguishable on conventional imaging; however, DSC measures of relative cerebral blood volume (rCBV) can differentiate the 2 entities on the basis of differences in inherent microvascular attenuation.1,2

We previously correlated localized DSC measurements with image-guided tissue analysis to establish rCBV threshold values that accurately identify histologically distinct subregions of tumor and PTRE within large enhancing lesions.2 Use of DSC and these thresholds provides a noninvasive diagnostic tool that can characterize lesion heterogeneity and help determine appropriate clinical management, because MR imaging lesions predominantly composed of tumor are often treated differently from predominantly PTRE lesions.

In clinical practice, however, the accuracy of rCBV measurements and representative rCBV maps can vary substantially depending on the DSC acquisition and postprocessing methods due to blood-brain barrier (BBB) disruption and resulting T1-weighted leakage and T2- and/or T2*-weighted imaging (T2/T2*WI) residual effects.3-6 These effects occur commonly in both tumor and PTRE lesions and can diminish test reliability, whether the rCBV maps are evaluated qualitatively (visual inspection), semiquantitatively, or quantitatively (region of interest analysis). Thus, it is paramount that the DSC technique be optimized to prevent or correct these inaccuracies and ensure that rCBV measurements maintain their correlation with histopathology.

Preload dosing (PLD) and baseline subtraction (BLS) techniques have been proposed as simple methods to minimize and correct for T1-weighted leakage and T2/T2*WI residual effects, respectively.3,5 These approaches are empiric, in contrast to mathematic modeling approaches such as gamma variate analysis.4,5,7 PLD administration of contrast agent before the DSC acquisition minimizes T1-weighted leakage effects by saturating the extravascular-extracellular-space tissue T1-weighted signal intensity, thereby diminishing T1-induced signal-intensity increases during the subsequent DSC contrast
injection. The BLS correction technique applied during post-processing integration prevents overestimation of rCBV caused by T2/T2*WI residual effects from leakage and/or recirculation, which causes persistent signal-intensity decreases following the initial first-pass contrast bolus.

Evidence suggests that PLD amount and other factors, such as incubation time, may impact the adequacy of T1-weighted leakage correction and rCBV measurement accuracy. Published PLD amounts currently range from 0.01 to 0.10 mmol/kg, at a 1.5T field strength; however, no general consensus exists regarding which PLD amount enables the most accurate rCBV estimation, whether PLD amounts >0.1 mmol/kg provide further benefit, and what optimal protocols are necessary at higher field strengths. Additionally, T2/T2*WI residual effects and the need for appropriate correction methods, such as BLS, may be related to PLD amount, further confounding accurate rCBV measurement.

There is a clear need in the medical imaging community to validate DSC techniques to determine standardized methods that provide clinically reliable measurements across multiple institutions. These DSC methods should also take into consideration the recent linkage between nephrogenic systemic fibrosis and total contrast dosage. Because DSC optimization impacts both clinical safety and measurement accuracy, the ultimate goal would be to identify the DSC protocol that maximizes test reliability while, at the same time, minimizing overall patient contrast load.

To our knowledge, there has not been a formal study that evaluates the dose-dependent relationship between PLD amount, T2/T2*WI correction, and rCBV accuracy to distinguish PTRE from tumor. We report a prospective study that correlates image-guided tissue analysis of enhancing MR imaging lesions with localized rCBV measurements at increasing PLD amounts, with and without BLS correction. We hypothesized that rCBV accuracy depends on PLD amount and that combining both PLD and BLS correction methods maximizes test accuracy in differentiating tumor from PTRE.

**Materials and Methods**

**Subject Recruitment and Exclusion Criteria**

From January 2007 to April 2008, we consecutively recruited previously treated patients with World Health Organization grade III and IV primary high-grade gliomas undergoing preoperative imaging for surgical re-resection of recurrent newly developed contrast-enhancing lesions on surveillance MR imaging. All patients had previously undergone initial treatment for their tumors, which consisted of combined surgical resection with adjuvant chemotherapy (which included temozolomide in all cases) and radiation therapy before enrollment into this study.

All patient information was anonymized for Health Insurance Portability and Accountability Act compliance. The institutional review board approved our study, and each subject gave written and informed consent.

The estimated glomerular filtration rate (eGFR) was calculated from serum creatinine levels, patient demographics, and age. Patients with eGFR < 60 mg/min/1.72 m² were excluded before enrollment. For each subject, we documented the presence of steroid therapy at the time of imaging and radiation therapy timing and dose. Criteria for exclusion of MR imaging data based on quality are described in detail in the “Coregistration of Stereotactic and DSC Image Datasets” subsection.

**Preoperative DSC and PLD Protocol**

Our project design consisted of a stepwise predosing protocol by using a broad range of increasing PLD amounts and incubation times before rCBV measurements, as previously described. We performed 6 sequential evenly timed DSC acquisitions, each using a half-dose (0.05 mmol/kg) bolus of gadodiamide (Omniscan; Nycomed Amersham, Oslo, Norway) injected at a rate of 3–5 mL/s (followed by a 20-mL normal saline flush) on the 10th time point of each series. Each 2-minute DSC acquisition consisted of 60 time points, and 1 minute separated the end of 1 DSC acquisition and the start of the next. Thus, sequential contrast injections were separated by 3 minutes. Note that the total contrast dosage following all 6 DSC acquisitions (0.3 mmol/kg) was within the US Food and Drug Administration–approved limit for this agent.

In summary, we acquired 6 separate DSC datasets by using 6 distinct DSC protocols in each patient, on the basis of which each suc-
cessive DSC acquisition and rCBV measurement were performed with incrementally increasing PLD amounts and incubation times from the sum of all prior injections, as depicted in Fig 1. For example, the first DSC acquisition was performed by using a protocol without PLD, whereas the sixth DSC acquisition was performed by using a protocol with 0.25-mmol/kg PLD administered during an incubation time of 15 minutes. In a previous article, we reported information from 1 of the 6 DSC MR imaging datasets, with the purpose of establishing the feasibility of correlating localized DSC values with stereotactic surgical tissue specimens to convey the clinical utility of rCBV in distinguishing tumor and PTRE. In that article, we referred to a separate citation, which compared the clinical accuracies of all 6 DSC datasets and ultimately supported our decision to report only the third sequential DSC dataset (acquired by using the following protocol parameters: preload dose of 0.1 mmol/kg and a total contrast dose of 0.15 mmol/kg). Because the general issue and methodology of pursuing DSC–MR imaging technique optimization were beyond the scope of that previous paper, we did not include the experimental data or statistical analyses from all 6 injections.

To address this distinctly important issue of DSC–MR imaging technique optimization, our current article describes in detail the methodology, experimental results, and clinical recommendations from the aforementioned citation, which includes information from all 6 DSC–MR imaging datasets in full. To this end, our current purpose was to describe the effects of T1-weighted and T2/T2*WI correction on the correlation with spatially accurate histopathology, specifically regarding the presence of and variation of the preload correction on the correlation with spatially accurate histopathology.

Coregistration of Stereotactic and DSC Image Datasets

Stereotactic MR imaging and the 6 DSC image datasets were transferred to an off-line Linux-based workstation to perform rigid-body coregistration by using Statistical Parametric Mapping (SPM; Wellcome Department of Imaging Neuroscience, London, UK) to help offset EPI image distortion. Before coregistration, images in each DSC dataset were visually evaluated by a neuroradiologist with >9 years’ experience with DSC (L.S.H.) to ensure that no significant patient motion occurred during the time series. Contrast bolus susceptibility changes typically confound accurate coregistration and image realignment techniques during a single acquisition; thus, obvious motion during any of the 6 acquisitions excluded all of that patient’s data from further analysis. For the remaining subjects, the fourth DSC dataset was arbitrarily chosen to provide a mean of 2 time-series images before and following contrast-bolus passage. The stereotactic MR imaging dataset and all other DSC time-series images were coregistered to that mean image for each subject. This process corrected patient motion between DSC acquisitions. A neuroradiologist (L.S.H.) visually validated coregistration accuracy.

DSC Data Postprocessing and rCBV Calculation

DSC data were analyzed by using an in-house Matlab-based (MathWorks, Natick, Massachusetts) MR perfusion analysis program with postprocessing steps based on previously published methods.

Calculation of Cerebral Blood Volume

After excluding the first 3 data points from each time series to allow tissue signal-intensity saturation, we generated whole-brain cerebral blood volume (CBV) maps by trapezoidal integration under the \( \Delta R^2(t) \) area curve from the start to the end of the first-pass contrast bolus on a voxel-by-voxel basis using 2 different methods (Fig 2): 1) integration without BLS; and 2) integration with BLS, which excluded a right triangular area whose hypotenuse was determined by the line extending from prebolus to postbolus baselines and whose height was determined by the difference between prebolus and postbolus \( \Delta R^2(t) \) values. Trapezoidal integration provides a common, robust, and simple method compared with other techniques such as gamma variate fitting. We determined the integration interval on the basis of the first-pass \( \Delta R^2(t) \) curves from normal brain parenchyma. We applied this integration interval to every voxel on the map. To account for possible noise and timing variation in the time-course data, we determined the postbolus \( \Delta R^2(t) \) baseline as the average of 5 \( \Delta R^2(t) \) values, which included the value at the end of the integration interval and values from the 4 successive time points.

rCBV Map Generation

A method of normalizing CBV maps to both normal-appearing gray matter (NAGM) and white matter (NAWM) contralateral to the enhancing lesion was previously described. However, despite BLS techniques, NAGM CBV demonstrated greater variability with increasing PLD amounts compared with NAWM (Fig 3), which could confound the evaluation of the PLD relationship with lesion rCBV. Due to NAWM CBV stability, we normalized CBV maps to the average of two 3 x 3 voxel regions of interest placed centrally within frontal and parietal NAWM to generate whole-brain rCBV maps. Note that changing the method of normalization will alter rCBV threshold values.
Coregistration of datasets enabled placement of 3 × 3 voxel-sized (0.4 cm²) regions of interest centrally within the previously recorded stereotactic dataset locations for each surgical tissue specimen. We calculated mean rCBV values and correlated these with corresponding specimen histopathology, as previously described.2 All regions of interest were inspected to ensure exclusion of visible vessels. DSC measurements were performed without knowledge of histopathology.

Tissue Histopathologic Diagnosis

All surgical specimens were formalin-fixed, paraffin-embedded, sectioned, and hematoxylin-eosin stained per standard diagnostic protocol at our institution. Without knowledge of DSC results, we histopathologically categorized each specimen as either tumor or PTRE, as previously described2: PTRE features included paucicellularity, lack of numerous atypical cells, lack of mitotic figures, and reactive cells including gemistocytes. Necrosis, if present, involved parenchyma rather than cellular tumor. Tumor-recurrence features included sheets and/or nests of atypical cells often with mitotic figures. Necrosis involved cellular tumor rather than parenchyma. Samples containing a mixture of both tumor and PTRE were classified as tumor, regardless of the percentage of tumor bulk. Only samples with pure radiation change (in the absence of tumor criteria) were categorized as PTRE. The sole presence of a few isolated, scattered atypical cells did not qualify as tumor categorization, as long as other neoplastic features were absent.

Statistical Analysis: rCBV Correlation with Histopathology and Region-of-Interest Comparison

We performed a primary analysis for all rCBV datasets by generating receiver operator characteristic (ROC) curves to distinguish tumor and PTRE samples. This was done for rCBV datasets acquired following all 6 PLD amounts and calculated both with and without BLS postprocessing. Thus, a total of 12 ROC curves were generated for the 36 tissue specimens. Areas under the curve (AUCs) were calculated for each ROC and statistically compared by using the Delong method. Sensitivity, specificity, and 95% confidence intervals (CIs) for distinguishing PTRE and tumor were generated from each ROC curve at a number of rCBV cutoff points (Analyse-it Software, Leeds, UK) to determine the optimal threshold value that maximized accuracy (defined as the average of sensitivity and specificity).

To evaluate possible covariance grouping effects from multiple intrasubject specimens, we performed a secondary analysis of ROC curves for all 12 conditions by using a smaller set of samples. We limited this analysis to single randomly selected specimens and corresponding rCBV values from each subject. We calculated AUCs for ROC curves and statistically compared them by using the Delong method to evaluate for the similarity in trends to the first analysis of the complete dataset. Results of the secondary analysis trended in the same direction as those of the primary analysis, though the secondary analysis did not reach statistical significance, likely due to the reduced sample size. Results of the primary analysis are presented herein. A biostatistician (A.C.D.) performed all analyses.

Results

Study Subjects, Tissue Specimens, and Histopathologic Analysis

Initially, 40 tissue specimens were collected from 13 subjects; however, 4 samples from 2 subjects were excluded from the data analysis due to motion during ≥1 of the sequential DSC
acquisitions. A total of 36 tissue samples (11 subjects) were included for final data analysis and categorized as tumor (n = 21) or PTRE (n = 15). The group mean and SD of craniotomy diameters were 3.97 ± 1.71 cm. The average tissue-specimen volume was approximately 0.3 cm³. Table 1 summarizes the patient demographics, subtype and grade of originally treated tumor, presence of steroid therapy, and radiation therapy type and timing. Of the 11 subjects, 3 (27.2.%) had only PTRE specimens, 5 (45.5%) had only tumor specimens, and 3 (27.2.%) had both types of specimens.

### rCBV versus Histopathology: ROC Analyses and Accuracy Comparison

Figure 4 summarizes the primary analysis results and the distribution of rCBV values for the tumor and PTRE groups for the 12 DSC methods, with respect to PLD amount and presence of BLS correction. Uncorrected test AUC (0.85) in the absence of any type of correction (either PLD or BLS) represented the comparison control, with a maximized test accuracy of 81% (sensitivity, 61.2%; specificity, 100%) over an rCBV threshold value range between 0.93 and 0.97 (95% CI, 58.3%–91.0%). BLS correction alone (in the absence of PLD correction) did not result in an appreciable increase in test AUC compared with that of controls. As PLD amount and incubation time increased, trends demonstrated that the test AUC increased in the absence of BLS; however, for no PLD amount (in the absence of BLS) did the AUC increase reach statistical significance compared with that of the control. When PLD and BLS correction methods were combined, test AUC significantly improved at specific PLD amounts and incubation times (Figs 4 and 5). Table 2 summarizes the percentage of tumor and PTRE specimens that were correctly diagnosed by rCBV measures by using the 12 specific PLD and BLS protocols. The protocol using a 0.1 mmol/kg PLD amount, an incubation time of 6 minutes, and BLS correction yielded the highest test AUC (0.99), with a test accuracy of 95.2% (sensitivity, 90.5%; specificity, 100%) over an rCBV threshold value range between 1.02 and 1.04 (95% CI, 73.9%–99.4%), while minimizing contrast dosage to the subjects.

### Discussion

In this study, we measured rCBV under varying acquisition and postprocessing conditions and correlated localized values with image-guided tissue histopathology to specifically answer the following questions: Does leakage correction improve DSC accuracy to distinguish subregions of PTRE from tumor recurrence, and does this correction depend on PLD amount? To our knowledge, this issue has not been previously addressed in a direct manner. Our data suggest that the test accuracy is approximately 81% without correction but increases to >95% following specific correction methods. These differences in rCBV accuracy can also be observed qualitatively (Fig 6). This underscores the clinical importance of optimizing the acquisition and postprocessing parameters for DSC. On the basis of these findings, our recommendations for maximizing rCBV accuracy in differentiating PTRE and tumor regions at 3T field strength are as follows:

1. Combining T1 leakage and T2/T2*WI residual correction is necessary to maximize test accuracy.
2. The PLD amount of 0.1 mmol/kg should be administered 6 minutes before the DSC acquisition injection to minimize T1 leakage effects.
3. BLS integration, or some other comparable T2/T2*WI correction, should be performed during postprocessing CBV calculation for T2/T2*WI leakage correction.
4. If time permits, conventional imaging could proceed during the “downtime” of the incubation period to help offset time delays in a busy clinical practice.

Previous studies have discussed how both T1 and T2/T2*WI leakage effects can confound accurate DSC measurements. 3,5 T1-weighted leakage effects increase signal intensity

---

Table 1: Patient demographic and clinical information

| Subject | Age (yr), Sex | Primary Tumor (grade) | RT Type, Dose, Timing (completed prior to imaging) | Steroids at Imaging |
|---------|--------------|-----------------------|-------------------------------------------------|--------------------|
| A       | 31, M        | AA (III)              | 60-Gy 3D conformal (9 mo)                        | Yes                |
|         |              |                       | 25-Gy salvage IMRT (2 mo)                        |                    |
| B       | 58, M        | GBM (IV)              | 54-Gy 3D conformal (22 mo)                       | Yes                |
|         |              |                       | 12-Gy gamma knife (5 mo)                         |                    |
| C       | 36, M        | GBM (IV)              | 60-Gy IMRT (2 mo)                                | None               |
|         |              |                       | 60-Gy IMRT (23 mo)                               | Yes                |
| D       | 56, M        | GBM (IV)              | 30-Gy IMRT (10 mo)                               |                    |
| E       | 45, F        | GBM (IV)              | 60-Gy 3D conformal (26 mo)                       | None               |
|         |              |                       | Excluded due to motion                           |                    |
| I       | 59, M        | GBM (IV)              | 37.5-Gy whole brain RT (8 mo)                    | Yes                |
|         |              |                       | 59.4-Gy IMRT (28.5 mo)                           |                    |
| J       | 62, M        | GBM (IV)              | 12-Gy gamma knife (15.5 mo)                      | None               |
| K       | 56, M        | Ana. GG (III)         | 54-Gy 3D conformal (12 mo)                       | None               |
| L       | 38, M        | Ana. GG (III)         | 54-Gy IMRT (24 months)                           | None               |
| M       | 43, M        | GBM (IV)              | 12-Gy gamma knife (11 mo)                        | None               |
|         |              |                       | 60-Gy 3D conformal (8 mo)                        | Yes                |
|         |              |                       | 10-Gy gamma knife (7 mo)                         |                    |

Note:—RT indicates radiation therapy; AA, anaplastic astrocytoma; GBM, glioblastoma multiforme; Ana. Gg, anaplastic ganglioglioma; IMRT, intensity modulated radiation therapy.

* Excluded from analysis due to motion during scanning.

† A single patient who underwent 2 separate surgeries 4.5 months apart.

---

---
and compete with susceptibility-induced signal-intensity decreases, resulting in an underestimation of rCBV;4-6,13 T2/T2*WI residual effects magnify signal-intensity decreases and overestimate rCBV.3,5 In reality, both effects are variably present during rCBV measurement, though technical and physiologic factors influence which effect predominates.3,5 A variety of possible correction algorithms have been proposed; however, we chose the PLD and BLS methods because they are each robust and technically facile, increasing the likelihood that a broad range of institutions and clinical practices could implement these optimization techniques.

Multiple factors can influence the adequacy of PLD correction of T1-weighted leakage effects, resulting in an underestimation of rCBV;4-6,13 T2/T2*WI residual effects magnify signal-intensity decreases and overestimate rCBV.3,5 In reality, both effects are variably present during rCBV measurement, though technical and physiologic factors influence which effect predominates.3,5 A variety of possible correction algorithms have been proposed; however, we chose the PLD and BLS methods because they are each robust and technically facile, increasing the likelihood that a broad range of institutions and clinical practices could implement these optimization techniques.

Multiple factors can influence the adequacy of PLD correction of T1-weighted leakage effects. Previous studies have proposed PLD dose-dependence;5,13 however, even if the PLD amount is maximized, the incubation time that allows the pre-injected contrast agent to diffuse into the extravascular-extra-cellular-space tissue plays as important a role in adequate correction as the amount itself. Boxerman et al4 administered 0.1-mmol/kg PLD immediately before the DSC injection for rCBV measurement, though reported insufficient correction. Conversely, Kassner et al5 reported sufficient correction with the equivalent PLD amount by waiting an incubation time of 6–10 minutes before the DSC injection for rCBV measurement. Their study at 1.5T is in agreement with our current results and the previously reported protocol at 3T.2 We administered the total PLD amount of 0.1 mmol/kg via 2 separate injections. We suspect that administering the total dose via a single injection 6 minutes before the DSC acquisition would yield comparable results. Nonetheless, current ongoing studies at our institution will help confirm this through clinical validation.

The type of contrast agent can also affect the degree of observed T1-weighted effects, as well as the efficacy of correction methods. Although this study evaluated gadodiamide, the contrast agent gadobenate dimeglumine (Multihance; Bracco, Milan, Italy) demonstrates approximately twice the in vivo T1 relaxivity as gadodiamide at equivalent doses, which suggests that there would be a greater T1 leakage effect with gadobenate. However, at the same time, the preloading dose of gadobenate may be more effective as well.13 This relationship may be confounded by gadobenate protein binding, which can offset the degree of extravascular contrast extravasation. Preliminary studies at our institution suggest that both contrast agents demonstrate approximately equal T2/T2*WI effects at equivalent doses. Regardless, further study is needed to help resolve these issues, particularly at high field strengths.

The optimal PLD and incubation time also depend on specific DSC pulse-sequence parameters that influence DSC T1-weighted sensitivity. Smaller FA sizes can reduce T1 leakage-effect sensitivity; however, this method does not completely eliminate these effects, and additional correction methods may still be necessary.5,7 There are also compromises to low FA, which include lower signal intensity-to-noise ratio and an increased magnitude of T2/T2*WI leakage effects.3,5 Use of short TRs can significantly increase T1-weighted sensitivity, negate any benefit of small FA techniques, and necessitate additional correction with PLD.5,17

There are several possible limitations to our study. The
Table 2: Percentage of tumor and PTRE specimens that were correctly diagnosed by rCBV thresholds measured under various DSC conditions

| PLD | rCBV<sup>a</sup> | Tumor No. (%) (Total = 21)<sup>b</sup> | PTRE No. (%) (Total = 15)<sup>c</sup> | rCBV<sup>a</sup> | Tumor No. (%) (Total = 21)<sup>b</sup> | PTRE No. (%) (Total = 15)<sup>c</sup> |
|-----|----------------|----------------------------------|----------------|----------------|----------------------------------|----------------|
| 0.0 | 1.00–1.06 | 13 (61.9) | 15 (100) | 0.93–0.96 | 13 (61.9) | 15 (100) |
| 0.05 | 1.15–1.16 | 17 (81.0) | 15 (100) | 1.09–1.13 | 15 (71.4) | 15 (100) |
| 0.1 | 1.02–1.03 | 19 (90.5) | 15 (100) | 1.14–1.15 | 18 (85.7) | 13 (86.7) |
| 0.15 | 0.96–0.98 | 19 (90.5) | 14 (93.3) | 1.01–1.04 | 19 (90.5) | 13 (80) |
| 0.2 | 1.22–1.22 | 17 (81) | 15 (100) | 1.35–1.38 | 17 (81.0) | 12 (80.0) |
| 0.25 | 0.99–1.12 | 19 (90.5) | 15 (100) | 1.19–1.20 | 20 (95.2) | 13 (86.7) |

Note:—PLD indicates preload dosing (mmol/kg); DCS, dynamic susceptibility-weighted contrast-enhanced MR imaging; BLS, baseline subtraction; rCBV, relative cerebral blood volume; PTRE, posttreatment radiation effect.

<sup>a</sup>Range of thresholds that maximized accuracy (average of sensitivity and specificity) to diagnose tumor and PTRE specimens under each test condition.

<sup>b</sup>Maximum number and percentage of specimens (out of a total of 21) correctly diagnosed by rCBV thresholds.

<sup>c</sup>Maximum number and percentage of specimens (out of a total of 15) correctly diagnosed by rCBV thresholds.

Although our 3T study used a smaller contrast dosage for each bolus injection compared with that in most reports at 1.5T, DSC imaging at a 3T field strength has been shown to provide similar data quality with a lower necessary dosage compared with 1.5T. We confirmed this in our study because we observed sufficient quality of contrast response to generate highly accurate rCBV measurements. In fact, the possibility of lowering the total contrast load may be viewed as a potential advantage to DSC imaging at higher field strengths.

We also recognize possible limitations regarding our subject population and tissue specimens. Our relatively small sample size relates, in part, to the expected inherent obstacles in prospective recruitment of patients with recurrent glioma undergoing surgical resection. Also, we excluded a portion of our subject population and tissue samples due to inadequate image quality from motion artifacts. In this study, we assumed that each of the tissue specimens and their respective rCBV values represented independent measures, despite the fact that patients often provided multiple specimens. In all cases, tissue specimens were taken from distinct and spatially isolated locations within the periphery of large enhancing lesions. Similarly, the regions of interest for rCBV calculation for corresponding specimens were also spatially distinct, without voxel overlap. We realize that certain intrasubject physiologic factors may influence DSC measurements for multiple specimens similarly within a particular subject. For instance, each subject’s cardiovascular and renal status may influence the shape and quality of the contrast bolus arterial input and/or the contrast agent clearance from the blood pool and extravascular extracellular space. Our secondary analysis addressed these issues of covariance grouping effects, at least in part, by limiting analysis to single randomly selected specimens from each subject. This analysis showed trends that were similar to those in our primary analysis of the complete dataset and suggest the absence of large intrasubject covariance.

BLS effectively corrects T2/T2*WI residual effects, which are often prominent following PLD administration. In our study, BLS proved necessary to achieve the highest degree of rCBV accuracy following PLD administration of 0.1 mmol/kg and an incubation time of 6 minutes. rCBV accuracy slightly diminished following PLD amounts exceeding 0.1 mmol/kg, both in the presence and absence of BLS correction. It was not until PLDs and incubation times reached 0.25 mmol/kg and
15 minutes, respectively, that accuracy increased again. There is evidence that T2/T2*WI leakage effects may be dose-dependent. One hypothesis to explain our results is that high PLD amounts (>0.1 mmol/kg) may lead to contrast agent accumulation in the extravascular extracellular space or vascular blood pool, magnifying T2/T2*WI residual effects. It is possible that longer incubation times (≥15 minutes) may allow enough fractional clearance of the contrast agent from the blood pool or extravascular extracellular space to diminish these effects. Wedeking et al reported an 80% decrease in the gadopentetate dimeglumine plasma concentration by 15 minutes following injection in animal models.

Given our results, it is also possible that BLS may not fully correct T2/T2*WI effects at very high PLD amounts (>0.1 mmol/kg) unless longer incubation times are used to allow adequate contrast agent clearance. Nonetheless, exceeding the 0.1 -mmol/kg PLD amount is unlikely to be clinically necessary or feasible, given our excellent accuracy with our single-dose PLD protocol as well as recent safety concerns regarding nephrogenic systemic fibrosis. In the future, it may be useful to explore the possible added benefit of other T2/T2*WI leakage-correction methods, such as mathematic modeling or dual-echo techniques.

Inaccuracies regarding the coregistration of DSC data with stereotactic biopsy locations during surgical resection may be another possible limitation to our study. Advantages of image-guided tissue analysis by using stereotactic surgical resection as opposed to stereotactic needle biopsy were discussed previously. In brief, small craniotomy sizes minimized brain shift. Craniotomies also allowed the neurosurgeon to visually validate stereotactic image location with intracranial neuroanatomic landmarks (ie, adjacent vascular structures, ventricle margins) to help correct for random brain shifts from opening the dura. For most cases, a neuroradiologist was present at surgery, and when necessary, the tissue-sample location was determined by consensus between the neuroradiologist and the neurosurgeon, though neither had knowledge of DSC–MR imaging measurements at the time of tissue collection. The neurosurgeon also avoided sampling from central necrotic fluid regions that would complicate accurate stereotactic localization. We also recognize that image distortion can reduce coregistration accuracy. To help reduce geometric distortions, we registered stereotactic and DSC datasets by using a rigid-body algorithm. Taking all of these issues into account, our experience suggests that the misregistration error is similar to that in methods using stereotactic needle biopsy (~1–2 mm). We also recognize limitations due to susceptibility effects, particularly at high field strengths and at the skull base, which would prevent analysis of specific regions due to poor image quality.

The entity “pseudoprogression” has been introduced in recent literature and describes how posttreatment reactive changes, typically resulting from a combination of radiation therapy and temozolomide, can mimic tumor recurrence primarily radiographically and clinically within months following treatment. Histopathologic diagnosis remains the crite- rion standard in these patients, though accurate diagnosis can be difficult in some cases. Specific histopathologic diagnostic criteria that can help improve accuracy were used in this study. Nonetheless, we recognize that diagnostic criterion standards are not completely accurate and thus present a possible limitation to this study.

Conclusions

rCBV accuracy in posttreatment gliomas depends on PLD amount and incubation time to minimize T1-weighted leakage effects as well as the presence of BLS correction to overcome T2/T2*WI residual effects. Combining the 2 methods significantly improves rCBV correlation with histopathology and enables highly accurate differentiation of PTRE and tumor growth.

Acknowledgments

We thank Mary Harrigan, Scott Beeman, Mike Purcell, and Brian Lenoski for their assistance. We also thank Zerrin Yetkin, MD, for her guidance and thoughtful discussions regarding this topic. We also appreciate the support of the Barrow Neurological Institute (BNI) Tumor Board, BNI patients, and their family members.

References

1. Sugahara T, Korogi Y, Tomiguchi S, et al. Post-therapeutic intra-axial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. AJNR Am J Neuroradiol 2006;27:901–09
2. Hu LS, Baxter LC, Smith KA, et al. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR Am J Neuroradiol 2009;30:552–58
3. Paulson ES, Schmainda KM. Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. Radiology 2006;240:603–13
4. Boxerman JL, Schmainda KM, Weisskoff RM. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol 2006;27:859–67
5. Kasnet A, Annesley DJ, Zhu XP, et al. Abnormalities of the contrast re-circulation phase in cerebral tumors demonstrated using dynamic susceptibility contrast-enhanced imaging: a possible marker of vascular tortuosity. J Magn Reson Imaging 2000;11:103–13
6. Lev MH, Ossunyan Y, Henson JW, et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol 2004;25:214–21
7. Johnson G, Wetzel SG, Cha S, et al. Measuring blood volume and vascular transfer constant from dynamic, T(2)*-weighted contrast-enhanced MRI. Magn Reson Med 2002;49:601–13
8. Bruening R, Kwong KK, Vevea MR, et al. Echo-planar MR determination of relative cerebral blood volume in human brain tumors: T1 versus T2 weight- ing. AJNR Am J Neuroradiol 1996;17:831–40
9. Sugahara T, Korogi Y, Kochi M, et al. Perfusion-sensitive MR imaging of gliomas: comparison between gradient-echo and spin-echo echo-planar imaging techniques. AJNR Am J Neuroradiol 2001;22:1306–15
10. Sorensen AG. Perfusion MR imaging: moving forward. Radiology 2008;249:416–17
11. Juhuri K, Vogel-Claussen J, Macura KJ, et al. MR imaging in patients at risk for developing nephrogenic systemic fibrosis: protocols, practices, and imaging techniques to maximize patient safety. Radiographics 2009;29:39–52
12. Hu LS, Baxter LC, Paine TL. Leakage corrected rCBV measurements using prebolus dosing applications in differentiating glioma recurrence from posttreatment effect at 3T field strength. In: Proceedings of the International Society for Magnetic Resonance in Medicine, Toronto, Ontario, Canada, May 3–9, 2008
13. Donahue KM, Krouwer HG, Rand SD, et al. Utility of simultaneously acquired gradient-echo and spin-echo cerebral blood volume and morphologic maps in brain tumor patients. Magn Reson Med 2000;43:845–53
14. Rosen BR, Belliveau JW, Vevea JM, et al. Perfusion imaging with NMR contrast agents. Magn Reson Med 1990;14:249–61
15. Boxerman JL, Hamberg JH, Rosen BR, et al. MR contrast due to intravascular magnetic susceptibility perturbations. Magn Reson Med 1995;34:555–66
16. Perko J, Aronen H, Kangasmäki A, et al. Evaluation of four postprocessing
methods for determination of cerebral blood volume and mean transit time by dynamic susceptibility contrast imaging. Magn Reson Med 2002;47:973–81
17. Sadeghi N, Salmon I, Decaestecker C, et al. Stereotactic comparison among cerebral blood volume, methionine uptake, and histopathology in brain glioma. AJNR Am J Neuroradiol 2007;28:455–61
18. Uematsu H, Maeda M. Double-echo perfusion-weighted MR imaging: basic concepts and application in brain tumors for the assessment of tumor blood volume and vascular permeability. Eur Radiol 2006;16:180–86
19. Roberts HC, Roberts TP, Brasch RC, et al. Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. AJNR Am J Neuroradiol 2000;21:891–99
20. Manka C, Träber F, Gieseke J, et al. Three-dimensional dynamic susceptibility-weighted perfusion MR imaging at 3.0 T: feasibility and contrast agent dose. Radiology 2005;234:869–77
21. Wedeking P, Eaton S, Covell DG, et al. Pharmacokinetic analysis of blood distribution of intravenously administered 153Gd-labeled Gd(DTPA)2- and 99mTc(DTPA) in rats. Magn Reson Imaging 1990;8:567–75
22. Poetker DM, Jursinic PA, Runge-Samuelson CL, et al. Distortion of magnetic resonance images used in gamma knife radiosurgery treatment planning: implications for acoustic neuroma outcomes. Otol Neurotol 2005;26:1220–28
23. Stadlbauer A, Ganslandt O, Buslei R, et al. Gliomas: histopathologic evaluation of changes in directionality and magnitude of water diffusion at diffusion-tensor MR imaging. Radiology 2006;240:883–10
24. Brandsma D, Stalpers L, Taal W, et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008;9:453–61
25. Perry A, Schmidt RE. Cancer therapy-associated CNS neuropathology: an update and review of the literature. Acta Neuropathol 2006;111:197–212